AGC
PEAR

Angelo Gordon & Co’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Angelo Gordon & Co’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100,000
Closed -$994K – 271
2021
Q3 		$994K Hold
100,000
– – 0.06% 112
2021
Q2 		$988K Buy
+100,000
New +$981K 0.05% 133

Other funds holding PEAR

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SGA
SB Global Advisers London, United Kingdom $861M AUM 71.72% 1-Year Est. Return
AV
Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return
PT
Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Angelo Gordon & Co's PEAR Position: Q4 2021 in Review

Angelo Gordon & Co sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q4 2021, closing a stake of 100,000 shares — an estimated $994K sold.

Angelo Gordon & Co first reported a position in PEAR in Q2 2021 and held it in 2 quarters. The position peaked at $994K in Q3 2021. 25 funds tracked by Wall St. Rank hold PEAR as of Q4 2021.

  • Angelo Gordon & Co reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
  • Angelo Gordon & Co sold 100,000 Pear Therapeutics, Inc. Class A Common Stock shares in Q4 2021, an estimated $994K.
  • Angelo Gordon & Co first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q2 2021 and held it in 2 quarters.
  • Angelo Gordon & Co's Pear Therapeutics, Inc. Class A Common Stock position peaked at $994K in Q3 2021.
  • 25 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q4 2021.

Based on Angelo Gordon & Co's 13F filing for Q4 2021, filed 14 Feb 2022.